Modular MedicalMODD
MODD
About: Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
Employees: 40
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
9% more funds holding
Funds holding: 32 [Q3] → 35 (+3) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.15% less ownership
Funds ownership: 35.38% [Q3] → 35.23% (-0.15%) [Q4]
25% less capital invested
Capital invested by funds: $25.9M [Q3] → $19.4M (-$6.55M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MODD.
Financial journalist opinion
Neutral
Accesswire
1 month ago
Modular Medical Announces BSI Group as Trusted Body for CE Mark Clearance
- Engaged BSI Group to start the process of obtaining regulatory clearance of the MODD1, next-generation insulin pump for the European market - Targeting Q1 2026 for expected clearance of the MODD1 in the E.U. SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 30, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced that BSI Group will serve as the notified body for the European regulatory clearance process.
Neutral
Accesswire
2 months ago
Modular Medical Announces Licensing and Partnership Agreement With Nudge BG
-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements -Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG. "We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery ("AID") to the marketplace," said Lane Desborough, CEO of Nudge BG.
Neutral
Accesswire
3 months ago
Modular Medical Announces Conference Call to Provide Business Update
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.
Neutral
Accesswire
3 months ago
Modular Medical Announces Pricing of $8.2 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P.
Neutral
Accesswire
3 months ago
Modular Medical Announces Proposed Public Offering
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also has granted the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) sold in the offering.
Neutral
Accesswire
4 months ago
Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it is a Gold sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today (ADEPT) Conference taking place at the Chicago Marriott Downtown on November 12 and 13,2024. The ADEPT Conference, which is the result of a collaborative effort between the American Diabetes Association and the T1D Exchange, will bring together key stakeholders focused on achieving health equity in type 1 and type 2 diabetes.
Neutral
Accesswire
4 months ago
Registration Is Now Open For Tribe Public's Webinar Event "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing" Featuring Modular Medical CEO On Monday, November 11, 2024
Meet with Modular Medical CEO, Jeb Besser Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing." The event is scheduled to begin at 8:00am pacific/11:00am eastern on Monday, November 11, 2024.
Neutral
Accesswire
4 months ago
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone -Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced successful results from its pre-clinical GLP-1 proof of concept study. "We are excited by the results of this pre-clinical, proof of concept study in a standard obese mouse model," stated Dr. David Maggs, M.D.
Neutral
Accesswire
5 months ago
Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1
SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on October 1, 2024. Company Webcast The Company's webcasted presentation will take place at 2:00 p.m.
Neutral
Accesswire
5 months ago
Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 product SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599.
Charts implemented using Lightweight Charts™